Changqing Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Changqing Yan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Zegao Zhou
Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China
2 shared publicationsChunxiao Pan
Burning Rock Biotech, Guangzhou, China
1 shared publicationDafang Zhang
Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China
1 shared publicationDanhua Wang
Burning Rock Biotech, Guangzhou, China
1 shared publication- Dong Zheng
College of Wildlife and Protected Area, Northeast Forestry University, Harbin, China
1 shared publication Hao Liu
Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publication
Latest Publications
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 14 (6) , 2559-2573
Identification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment
Background: The family of coiled-coil domain-containing (CCDC) proteins participates in a wide range of physiological functions and plays a pivotal role in governing the invasion and metastasis of malignant tumor cells. Nonetheless, the precise mechanism governing the interaction among the immune microenvironment, hypoxia pathway, and proliferation in hepatocellular carcinoma (HCC) remains elusive. In this study, our objective was to identify the prognostic significance of CCDC family genes in HCC. Methods: We conducted an analysis of RNA-seq data from HCC patients sourced from The Cancer Genome Atlas (TCGA) database. Our analysis involved comparing the expression profiles of 168 CCDC family genes between tumor and normal tissues to identify differentially expressed genes (DEGs). The prognostic value of these genes was verified using overall survival (OS) data from TCGA-LIHC patients, employing Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier plots. Subsequently, we constructed a prognostic signature known as the CCDC score and validated it using additional datasets (ICGC-LIRI-JP and GSE14520). Additionally, we performed functional enrichment analysis and conducted an assessment of the tumor immune microenvironment (TIME). Results: We identified 34 DEGs of the CCDC family. Among them, six DEGs (CCDC6/22/51/59/132/134) were upregulated and associated with poor prognosis. Higher CCDC score was an independent predictor of poor OS in TCGA-HCC patients (PConclusions: The CCDC score, derived from six CCDC genes, exhibits remarkable expression levels in liver cancer and holds promise as an independent prognostic indicator. Our bioinformatics analysis revealed a high CCDC score is strongly associated with activation of the hypoxia pathway and an immunosuppressive tumor microenvironment in HCC. This profound finding may serve as a cornerstone for innovative targeted drug therapies and pave the way for further investigations into the underlying mechanisms of CCDC-related carcinogenesis in liver cancer.
- 1 December 2023
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 14 (6) , 2559-2573
Open AccessIdentification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment
Background: The family of coiled-coil domain-containing (CCDC) proteins participates in a wide range of physiological functions and plays a pivotal role in governing the invasion and metastasis of malignant tumor cells. Nonetheless, the precise mechanism governing the interaction among the immune microenvironment, hypoxia pathway, and proliferation in hepatocellular carcinoma (HCC) remains elusive. In this study, our objective was to identify the prognostic significance of CCDC family genes in HCC. Methods: We conducted an analysis of RNA-seq data from HCC patients sourced from The Cancer Genome Atlas (TCGA) database. Our analysis involved comparing the expression profiles of 168 CCDC family genes between tumor and normal tissues to identify differentially expressed genes (DEGs). The prognostic value of these genes was verified using overall survival (OS) data from TCGA-LIHC patients, employing Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier plots. Subsequently, we constructed a prognostic signature known as the CCDC score and validated it using additional datasets (ICGC-LIRI-JP and GSE14520). Additionally, we performed functional enrichment analysis and conducted an assessment of the tumor immune microenvironment (TIME). Results: We identified 34 DEGs of the CCDC family. Among them, six DEGs (CCDC6/22/51/59/132/134) were upregulated and associated with poor prognosis. Higher CCDC score was an independent predictor of poor OS in TCGA-HCC patients (PConclusions: The CCDC score, derived from six CCDC genes, exhibits remarkable expression levels in liver cancer and holds promise as an independent prognostic indicator. Our bioinformatics analysis revealed a high CCDC score is strongly associated with activation of the hypoxia pathway and an immunosuppressive tumor microenvironment in HCC. This profound finding may serve as a cornerstone for innovative targeted drug therapies and pave the way for further investigations into the underlying mechanisms of CCDC-related carcinogenesis in liver cancer.
- Open Access
- 1 April 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (2) , 847-858
Bee venom protects against pancreatic cancer via inducing cell cycle arrest and apoptosis with suppression of cell migration
Background: Pancreatic cancer seriously threatens human health. Bee venom is a mixture of enzymes, peptides, and amines. Due to its biological activity, bee venom is widely used as an anti-inflammatory agent and pain reliever. However, little is known about the effect of bee venom on pancreatic cancer. Methods: Firstly, the Cell Counting Kit-8 (CCK-8) assay was conducted to analyze the cytotoxicity of bee venom on PANC-1 and AsPC-1 cells. Then, we evaluated the cell cycle and apoptosis by flow cytometry and the terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay. In addition, cell migration was analyzed by the cell scratch test and Transwell assay. Western blot was performed to assess the expression of proteins involved in the regulation of cell cycle arrest and apoptosis. Results: Results demonstrated that bee venom significantly suppressed cell proliferation via inducing cell cycle arrest and apoptosis with suppression of cell migration. Bee venom induced S phase arrest and ameliorated the protein expression of cyclins and cyclin-dependent kinases (CDKs). At the same time, bee venom can activate the p53–p21 pathway. Experimental data also showed that bee venom induced cell apoptosis and impeded cell migration. Conclusions: The present study revealed that bee venom could effectively inhibit tumor progression in pancreatic cancer cells, indicating the possibility of bee venom as an anti-tumor drug in pancreatic cancer.
- 1 April 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (2) , 847-858
Open AccessBee venom protects against pancreatic cancer via inducing cell cycle arrest and apoptosis with suppression of cell migration
Background: Pancreatic cancer seriously threatens human health. Bee venom is a mixture of enzymes, peptides, and amines. Due to its biological activity, bee venom is widely used as an anti-inflammatory agent and pain reliever. However, little is known about the effect of bee venom on pancreatic cancer. Methods: Firstly, the Cell Counting Kit-8 (CCK-8) assay was conducted to analyze the cytotoxicity of bee venom on PANC-1 and AsPC-1 cells. Then, we evaluated the cell cycle and apoptosis by flow cytometry and the terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay. In addition, cell migration was analyzed by the cell scratch test and Transwell assay. Western blot was performed to assess the expression of proteins involved in the regulation of cell cycle arrest and apoptosis. Results: Results demonstrated that bee venom significantly suppressed cell proliferation via inducing cell cycle arrest and apoptosis with suppression of cell migration. Bee venom induced S phase arrest and ameliorated the protein expression of cyclins and cyclin-dependent kinases (CDKs). At the same time, bee venom can activate the p53–p21 pathway. Experimental data also showed that bee venom induced cell apoptosis and impeded cell migration. Conclusions: The present study revealed that bee venom could effectively inhibit tumor progression in pancreatic cancer cells, indicating the possibility of bee venom as an anti-tumor drug in pancreatic cancer.